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Abstract. Optical devices for measuring protoporphryin IX (PpIX) fluorescence in tissue are routinely validated
by measurements in optical phantoms. Yet there exists limited data to form a consensus on the recipe for phan-
toms that both mimic the optical properties found in tissue and yield a reliable and stable relationship between
PpIX concentration and the fluorescence remission intensity. This study characterizes the influence of multiple
phantom components on PpIX fluorescence emission intensity, using Intralipid as the scattering source, bovine
whole blood as the background absorber, and Tween as a surfactant to prevent PpIX aggregation. Optical mea-
surements showed a linear proportionality (r > 0.99) between fluorescence intensity and PpIX concentration (0.1
to 10 μg∕mL) over a range of Intralipid (1 to 2%) and whole blood (0.5 to 3%) for phantoms containing low
surfactant (≤0.1%), with fluorescence intensities and scattering and absorption properties stable for 5 h
after mixing. The role of surfactant in PpIX phantoms was found to be complex, as aggregation was evident
in aqueous nonturbid phantoms with no surfactant (0% Tween), and avoided in phantoms containing
Intralipid as the scattering source with no additional or low amounts of added surfactant (≤0.1% Tween).
Conversely, phantoms containing higher surfactant content (>0.1% Tween) and whole blood showed inter-
actions that distorted the fluorescence emissions. © The Authors. Published by SPIE under a Creative Commons Attribution 3.0
Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI.
[DOI: 10.1117/1.JBO.21.3.035003]
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1 Introduction
Protoporphyrin IX (PpIX) is a photosensitizer and fluorophore
of interest both for experimental photo-based therapies and for
diagnostic assessment of suspicious tissue during surgery.1
While PpIX occurs naturally in the body, temporary enhance-
ment can be induced by administration of aminolevulinic acid
(ALA), a nonfluorescent prodrug that serves to bypass the neg-
ative feedback controls of the heme-biosynthesis pathway and
results in a selective retention of PpIX in tissue with altered met-
abolic activity.2,3 In the field of dermatology, topical application
of ALA induces PpIX in precancerous and cancerous skin
lesions, where PpIX serves as a photosensitizer for photody-
namic therapy.4,5 Dosimetry studies have shown that optical
measurements of PpIX fluorescence may provide insight into
patient-specific responses to therapy.6–8 In the field of neurosur-
gery, oral administration of ALA is used to induce PpIX accu-
mulation in malignant tumors in the brain.2 Multiple clinical
investigations are considering the use of optical measurements
of PpIX fluorescence to increase contrast between tumor and
surrounding normal cortex.9–14 Research in these clinical spe-
cialties has led to the development of a variety of approaches to
optically sample PpIX fluorescence emissions from tissue.1,15
Basic imaging approaches sample raw PpIX fluorescence
intensity resulting from wide-field illumination with the excita-
tion wavelength,7,9,16 which provides a relative evaluation of
PpIX concentration changes within a field of view. Spectro-
scopic approaches are able to un-mix fluorescence emissions
originating from both PpIX and endogenous fluorochromes8,17–20
and correct for distortions from background optical proper-
ties,8,17–21 with many of these approaches returning quantitative
metrics of PpIX fluorescence that are comparable between dif-
ferent measurement locations. One requirement shared by all of
these optical measurement devices is that the sampled fluores-
cence intensity attributed to PpIX be proportional to PpIX
concentration. This validation step is often performed using
measurements of tissue-simulating optical phantoms.8,16,20,22–25
Such benchtop optical phantom studies are used to determine
the lower limits of detection of PpIX in turbid media, and
also are used to assess the sensitivity of collected fluorescence
emissions to variations in background optical properties.
In order for measurements in optical phantoms to be repre-
sentative of measurements in tissue, the phantoms need to mimic
the wavelength-dependent optical properties endogenous to tis-
sue. Figure 1 shows the absorption and emission spectra of
PpIX, as well as the absorption coefficient of oxygenated and
deoxygenated hemoglobin, which are dominant endogenous
absorbers in tissue. PpIX is commonly excited in the blue wave-
length region, where a strong absorption band at 405 nm yields
efficient fluorescence generation. However, blue excitation
competes with background absorption from the soret band of*Address all correspondence to: Stephen Chad Kanick, stephen.c.kanick@
dartmouth.edu
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hemoglobin, resulting in a tissue-surface-weighted estimate of
PpIX. Methods that excite PpIX in the red (near 633 nm)
yield a less efficient fluorescent signal but avoid the strong
hemoglobin-based attenuation and achieve deeper sampling.
Previously reported studies designed to validate PpIX quantifi-
cation systems have used optical phantoms with components
that closely match the wavelength dependence of absorption and
scattering observed in tissue,8,16,20,22–25 including the use of
Intralipid as a scattering source and whole blood as an absorber.
While these components are not recognized as optical property
standards due to a lack of quality control, they have been exten-
sively characterized to provide combinations of wavelength-
dependent scattering26–28 and absorption29 properties in the exci-
tation and emission bands for PpIX that closely mimic tissue.
An additional, yet critical, aspect to consider is the hydropho-
bicity of PpIX, which can lead to aggregation and decreased
fluorescence when placed into an aqueous solution.30,31 To mit-
igate this effect, surfactants such as polyethylene glycol sorbitan
esters (e.g., Tween), are commonly added to aqueous PpIX
phantoms to prevent aggregation.8,20,22–25 However, surfactants
are also known to lyse or otherwise affect blood cells,32 which in
turn can impact the optical properties of the phantom solution.
Yet, to date, a methodical study to examine interactions of con-
stituents and optical property stability in PpIX phantoms has not
been reported.
This study aims to identify an optimal and standardized PpIX
phantom recipe for instrument validation and performance
assessment studies. Toward that end, the study considers how
different recipes for PpIX tissue-simulating optical phantoms in-
fluence the proportionality between sampled fluorescence and
the PpIX concentration contained within the phantom. The
study highlights how certain combinations of the basic recipe
components can have profound and unintended influences on
collected PpIX fluorescence emissions. The presented data
informs the standardization of the phantom making process
for tissue-mimicking PpIX phantoms for fluorescence detection
systems.
2 Materials and Methods
Tissue-simulating PpIX phantoms created using various recipes
were used to characterize the effects of phantom composition
on fluorescence emission spectra. The optical phantoms were
measured using either a spectrofluorometer for nonscattering
solutions, or with a fiber-optic-based spectroscopy system for
phantoms containing a scattering agent.
2.1 Optical Phantom Preparation
Nonturbid (i.e., clear) phantoms were prepared to characterize
the fluorescence emission of PpIX in an aqueous solution in the
presence of various amounts of surfactant. For this set, 15 phan-
toms (10 mL each) were prepared with PpIX (Sigma-Aldrich,
St. Louis, Missouri) solubilized in dimethyl sulfoxide (DMSO)
to yield concentrations of (0.1, 1, 10) μg∕mL, Tween 20 (Sigma-
Aldrich) in volume fractions (TVF) of (0, 0.1, 0.5, 1, 5)%, and
the balance completed with phosphate-buffered saline (PBS).
An additional phantom set was also measured using egg yolk
(more specifically the amphipathic phospholipid contents of
egg yolk33,34) as a surfactant, with egg yolk volume fractions of


































Fig. 1 Absorption and emission of PpIX compared to absorption of Hb and HbO2. A horizontal line at
405 nm highlights a commonly used excitation wavelength to measure PpIX fluorescence.
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Two phantom sets were constructed to characterize PpIX
fluorescence in turbid phantoms in the presence of surfactant:
one set containing Intralipid 20% (Fresenius Kabi, Uppsala,
Sweden) as the scattering agent with no background absorber,
and a second set containing both Intralipid and bovine whole
blood (Lampire, Ottsville, Pennsylvania) as a background
absorber. Each phantom in this set contained 1.5% lipid volume
fraction (LVF), while the absorbing set of phantoms also con-
tained 2% blood volume fraction (BVF). PpIX was solubilized
using DMSO at a stock concentration of 1 mg∕mL; dilutions
from this stock were used to achieve the desired PpIX concen-
tration in each phantom. In total, 50 phantoms (20 mL each)
were constructed to include a range of five PpIX concentrations
[(0.1, 0.3, 1, 3, 10) μg∕mL], each prepared with five different
TVF [(0, 0.1, 0.5, 1, 5)%]. Additionally, a phantom set with
1.5% LVF, 2% BVF, and 1 μg∕mL PpIX was sampled with
a more granular set of TVF values [(0, 0.1, 0.5, 1, 2, 3, 4,
5)%]. To confirm the stability and reliability of Intralipid as a
scatterer and blood as an absorber for fluorescence measure-
ments, two additional sets of phantoms were made varying LVF
and BVF at a TVF of 0.1% for a range of PpIX concentrations
[(0.1, 0.3, 1, 3 10) μg∕mL]. This included variation of BVF
[(0.5, 1, 2, 3)%] with a fixed LVF of 1.5%, and also variation
of LVF [(1, 1.5, 2)%] with a fixed BVF of 2%. Table 1 provides
a detailed overview of the combinations of constituents used
within each of the phantom sets.
2.2 Spectroscopic Equipment
Nonturbid optical phantoms were measured using the
FluoroMax-3 spectrofluorometer (HORIBA Scientific, Edison,
New Jersey). During the measurements, excitation light at
405 nm was projected on the samples, and fluorescence emis-
sions were collected over the range of (600 to 750) nm (Δλ ¼
1 nm) at an angle perpendicular to excitation light. Turbid opti-
cal phantoms were measured using a custom-built fiberoptic
probe system described in detail previously.18 The system
included a hand-held probe that contained four active fiber
optic leads of 200 μm in diameter: a detector fiber [connected
to a spectrophotometer (USB2000+, Ocean Optics, Dunedin,
Florida)], a blue light-emitting diode (LED) (405 nm) source
(LedEngin Inc. Santa Clara, California) fiber with a center to
center separation from the detector of 260 μm, and two fibers
that lead to a white LED light source (LedEngin Inc. Santa
Clara, California) spaced 260 and 520 μm center-to-center from
the detector. The four fiber-optic leads were connected to a mul-
tiplexer (Model MPM-2000, Ocean Optics, Dunedin, Florida)
such that the detected light could be measured sequentially
by the spectrophotometer. The probe was controlled using
LabVIEW (National Instruments, Austin, Texas) and measure-
ments were taken with the probe tip placed few millimeters
beneath the surface of the liquid phantom.
2.3 Data Sampling
Optical measurements were performed in the phantoms immedi-
ately after components were mixed and sampling was repeated
every hour for 5 h. All phantoms were stored in the dark
between measurements to prevent PpIX photobleaching from
ambient light and mixed before measurement by inverting the
sample multiple times to re-mix constituents and prevent blood
pooling prior to each optical measurement. All phantoms were
stored at ambient room temperature (≈21°C) except for two
additional phantoms [LVF = 1.5%, BVF = 2%, PpIX = 1
μg∕mL, TVF = (0.5, 5)%] that were stored in a refrigeration
unit (≈2°C) during the 5-h period. Each optical measurement
consisted of a paired measurement of reflectance, using white
light, and fluorescence, using blue light. Optical measurements
were repeated in each phantom multiple times.
2.3.1 Reflectance fitting
Raw reflectance spectra measured from a sample was calibrated
by subtracting the dark current, dividing by integration time, and
then normalizing by a ratio of the model-estimated and mea-
sured white light reflectance spectra of an Intralipid reference
phantom containing 2% LVF. Model estimates for the calibra-
tion reference was calculated using the optical properties in
Intralipid reported previously,26 and constrained diffusion theory
was used as the inversion technique between spectra and optical
properties within this study. Work by Kim et. al35 details the
mathematical model for multi-fiber applications, which returns
an estimate of diffuse reflectance using estimates of the absorp-
tion coefficient (μa), the reduced scattering (μ 0s), and the source-
detector separation (ρ) as inputs such that RðλÞ ¼ fðμaðλÞ;
μ 0sðλÞ; ρÞ. μ 0sðλÞ was estimated using a wavelength dependent
power law relationship,36 as







where μ 0sðλoÞ and b, the scattering slope, are fitted values and λo
was set to 550 nm. μaðλÞ was modeled as a linear sum of all
significant chromophores, as
Table 1 Detailed list of components used in the phantom sets.
Phantom set PpIX (μg∕mL) LVF (%) BVF (%) TVF (%) Egg yolk (%)
Nonturbid—TVF 0.1, 1, 10 0 0 0, 0.1, 0.5 1, 5 0
Nonturbid—Egg yolk 0.1, 1, 10 0 0 0 0, 0.1, 0.5, 1, 5
Turbid—TVF #1 0.1, 0.3, 1, 3, 10 1.5 2 0, 0.1, 0.5, 1, 5 0
Turbid—TVF #2 1 1.5 2 0, 0.1, 0.5, 1, 2, 3, 4, 5 0
Turbid—BVF 0.1, 0.3, 1, 3, 10 1.5 0.5, 1, 2, 3 0.1 0
Turbid—LVF 0.1, 0.3, 1, 3, 10 1, 1.5, 2 2 0.1 0
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EQ-TARGET;temp:intralink-;e002;63;752μaðλÞ ¼ BVF½StO2εoxyHba ðλÞ þ ð1 − StO2ÞεdeoxyHba ðλÞ; (2)
where, BVF is the blood volume fraction, StO2 is the microvas-
cular saturation, and εoxyHba and ε
deoxyHb
a are the wavelength-
dependent specific absorption coefficients (cm−1) of fully oxy-
genated and deoxygenated hemoglobin, respectively. Reflec-
tance fits were performed over the wavelength range 450–
650 nm, with parameters estimated in the set: [BVF, StO2,
μ 0sðλoÞ, and b].
2.3.2 Fluorescence fitting
Fluorescence spectra were calibrated by subtracting the dark
current and dividing by integration time before fitting the result-
ing spectra as a linear combination of emission profiles from
PpIX, PpIX photoproducts, and autofluorescence emission, as
EQ-TARGET;temp:intralink-;e003;63;577FRawðλÞ ¼ ½FLPpIXεPpIXe þ ΣðFLPPεPPe Þ þ FLAFεAFe ; (3)
where εPpIXe , εPPe , and εAFe are normalized wavelength-dependent
emission profiles and FLPpIX, FLPP, and FLAF are fitted esti-
mates of the fluorescence contribution [a.u.] of PpIX, PpIX’s
photoproducts, and autofluorescence, respectively. Estimates
obtained using Eq. (3) are influenced by fluorescence distortions
due to optical properties. To correct for these distortions, we
utilized a fluorescence quantification algorithm described by
Kim et. al.18 used to extract intrinsic fluorescence (FQuant) from





where λx and λm are the excitation and emission wavelengths,
respectively. Fluorescence fitting with FQuant is performed as
described in Eq. (3), where G is a scalar function with units
of (a:u:∕μg∕mL) that relates fitted estimates of PpIX fluores-
cence intensity [a.u.] to PpIX concentration in units of
(μg∕mL), such that CPpIX ¼ ðGÞFLPpIXQuant. Fluorescence fits were
performed over the wavelength range 603–721 nm, with param-
eters estimated in the set: (FLPpIX, FLPP, FLAF) from raw fluo-
rescence, and (CPpIX, CPP, CAF) from quantitative fluorescence.
2.3.3 Analysis of phantom stability
For phantoms sets considering controlled variation in surfactant
content (e.g., TVF variation), the time-dependent stability of
optical parameters (i.e., FLPpIX, μ 0s, and BVF) were evaluated by
comparing parameter estimates at a sampled time [i.e., (1, 2, 3,
4, 5) h] after preparation to the parameter estimate recovered
immediately following preparation of the phantom at the (0)
hour time point. For phantom sets considering controlled varia-
tion in background optical properties (e.g., LVF and BVF
variation) the estimated PpIX concentration (CPpIX) was also
compared with the known PpIX concentration. Linear propor-
tionality between recovered optical parameters and the true
parameter values in the phantom set was established using
Pearson product-moment correlation. Optical parameter esti-
mates were analyzed to identify outliers based on comparisons
with repeat measurements within each phantom; specifically, the
threshold for exclusion was specified as an absolute difference
from the mean of the repeats that was more than five times the
median absolute deviation of the repeats.
3 Results
3.1 PpIX Fluorescence in Nonturbid Phantoms
Figure 2 shows fluorescence spectra acquired with the spectro-
fluorometer from a clear solution containing 1 μg∕mL PpIX
with various TVF. Emission spectra from samples containing sur-
factant show repeatable fluorescence profiles with a coefficient of
variation for the peak fluorescence for all TVF of <4%. However,
the sample containing no surfactant shows a strongly reduced
fluorescence emission, with a reduction of 98% compared with
the average of samples containing surfactant. Inspection of these
data shows that in order to observe any significant PpIX fluores-
cence, a surfactant must be introduced to prevent aggregation.
These data suggest that relatively small amounts of Tween
(i.e., 0.1%) were sufficient to prevent PpIX aggregation.
3.2 PpIX Fluorescence in Turbid Phantoms
Figure 3 shows PpIX fluorescence emission results collected in
turbid phantoms containing 1.5% LVF and no significant back-
ground absorption. Figure 3(a) shows sample emission spectra
for phantoms with 1 μg∕mL PpIX and various TVF that were
measured immediately following phantom preparation (i.e.,
time 0 h) and 5 h after preparation. These data show no observ-
able differences in fluorescence emission for all sampled TVF
for either of the sampled time points. Figure 3(b) shows fitted
estimates of PpIX fluorescence at intermediate time points over
the range of 0 to 5 h. Here, PpIX fluorescence was not influ-
enced by the addition of Tween, with the maximum observed
deviation of <7% among samples containing Tween volume
fractions of [(0, 0.1, 0.5, 1, 5)%]. Figure 3(c) shows that esti-
mates of μ 0s (550 nm) were stable over time, with the maximum
observed decrease of <1% over 5 h. The recovered value of μ 0s
(550 nm) was also stable in the presence of surfactant variation,
with a maximum deviation of <1.5% observed for TVF
≤4%, while phantoms containing 5% TVF showed a slight
decrease of <8% in μ 0s; such a deviation may be due either to
Tween effects or to variation in the phantom making process.
Figures 3(d) and 3(e) show that the estimated and known
PpIX concentrations were highly correlated (r > 0.99) for all
TVF at 0 and 5 h.
The data in Fig. 3 showed that PpIX fluorescence was not
influenced by the presence of surfactant, an observation that
seemed to contradict the conclusion that surfactant was neces-
sary to produce measurable PpIX fluorescence in an aqueous

















Fig. 2 Fluorescence spectra of 1 μg∕mL PpIX in PBS (nonturbid) for
multiple Tween 20 concentrations.
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Intralipid phantoms with no added Tween suggested that one of
the compounds in the lipid emulsion acted as a surfactant. The
ingredients of the lipid emulsion included 20% soybean oil,
1.2% egg yolk phospholipids, 2.25% glycerin, and water.
Egg yolk phospholipids were identified as having amphipathic
properties, and it was hypothesized that this component may act
as a surfactant. Figure 4 shows emission from nonturbid phan-
toms containing 1 μg∕mL PpIX and various amounts of egg
yolk, showing an average decrease in fluorescence of <95%
without egg yolk. These results suggest that the egg yolk phos-
pholipids contained within Intralipid may act as a surfactant to
prevent aggregation of PpIX within an aqueous tissue phantom.
3.3 PpIX Fluorescence in Turbid Phantoms
Containing Whole Blood
Figure 5 shows PpIX fluorescence emission results that were
collected in turbid phantoms containing scattering (1.5% LVF)
and a strong background absorber (2% BVF). Figure 5(a) shows
sample emission spectra for phantoms with 1 μg∕mL PpIX and
various TVF values at 0 and 5 h after preparation, with substan-
tial reduction in remission intensity observed with increasing
TVF values between the 0 and 5 h time points. Figure 5(b)
shows the evolution of PpIX fluorescence over time for each
sampled TVF; these data are for for 1 μg∕mL but observed
trends were similar for all PpIX concentrations sampled (data
not shown). The data show that the change in fluorescence inten-
sity with time is not linearly influenced by TVF; after 5 h the
average decrease in measured fluorescence was <98% for phan-
toms containing 5% TVF, 47% for phantoms containing 1%
TVF, and <10% in phantoms containing 0.1% and 0% TVF.
Figure 5(c) shows estimates of μ 0s versus time for the phantoms,
with temporal variation <12% observed for all TVF, suggesting
stability of the lipid induced scattering. Figure 5(d) shows esti-
mates of BVF versus time, showing a TVF-dependent decrease
in estimated BVF over time. The decreases in BVF were highly
correlated (r ¼ 0.94) with reductions in PpIX fluorescence over
time as shown in panel (b). These data suggest that an interac-
tion between whole blood and Tween can complicate the stabil-
ity of PpIX fluorescence over time, and that low volume
fractions of surfactant (i.e., 0 to 0.1% TVF) in Intralipid yield
a temporally stable fluorescence response. This hypothesis was
supported by microscopic inspection of samples from phantoms
obtained at the 5-h time point, revealing intact erythrocytes for 0
and 0.1% TVF phantoms, and lysed erythrocytes in the solution
containing 5% Tween (data not shown). Figure 5(e) shows linear
proportionality between PpIX fluorescence intensity and known
PpIX concentration immediately after mixing for all TVF sam-
ples (r ¼ 0.99). Figure 5(f) shows accurate recovery of known
PpIX concentration (r > 0.99) for TVF ≤0.1% at 5 h after
phantom preparation, but substantial TVF-dependent decreases
in fluorescence intensity over time for TVF > 0.1%. Figure 6
shows the spectral features of the measured and model-fitted
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Fig. 3 (a) Fluorescence spectra sampled in phantoms containing 1 μg∕mL PpIX, 1.5% LVF, and (0, 0.1,
0.5, 1, 5)% TVF at hour 0 and hour 5. Dynamic response of optical parameters for various TVF shown for
(b) fitted PpIX fluorescence, and (c) μ 0s (550 nm). Estimated versus known PpIX concentrations for multi-
ple TVF at (d) hour 0 and (e) at hour 5. Line shows linear fit to 0.1% TVF data.
Fig. 4 Fluorescence spectra of PpIX in a clear solution containing
various concentrations of egg yolk.
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through (c)] and 5% TVF [(d) through (f)]. A time-dependent
deterioration of the absorption signature of hemoglobin is
observed in the phantom containing 5% TVF; the time-
line of these spectral changes is consistent with the decrease
in fluorescence and BVF estimates reported in Figures 5(b)
and 5(d).
The surfactant-induced degradation of fluorescence intensity
over time shown in Figure 5 was observed in phantoms stored at
room temperature. Figure 7 considers the comparative influence
of reducing temperature by storing phantoms in a refrigeration
unit. PpIX fluorescence measured in 5% TVF showed a slight
reduction in the rate of fluorescence quenching for refrigerated
versus unrefrigerated samples, with 38% versus 88% decrease in
fluorescence at 1 h following preparation; however the cooler
temperature did not yield a stable phantom, with a reduction
of 81% fluorescence at the 5-h mark. Conversely, for the
0.5% TVF phantom, there was no observed difference between
the refrigerated and unrefrigerated cases. These results further
support the hypothesis that the origin of fluorescence variation
is not due to natural decomposition of either the Intralipid or
blood but is instead caused by interactions between surfactant
and erythrocytes.
Time (h) Time (h)
Time (h)
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Fig. 5 Fluorescence spectra sampled in phantoms containing 1 μg∕mL PpIX, 1.5% LVF, 2% BVF, and
(0, 0.1, 0.5, 1, 2, 3, 4, 5)% TVF at hour 0 and hour 5. Dynamic response of optical parameters for various
TVF shown for (b) fitted PpIX fluorescence, (c) μ 0s (550 nm), and (d) BVF. Estimated versus known PpIX
concentrations for multiple TVF at (e) hour 0 and (f) at hour 5. Line shows linear fit to data for 0.1% TVF.

































Hour 0 Hour 2 Hour 5
Hour 0 Hour 2 Hour 5
Fig. 6 Fitted reflectance spectra from phantoms containing 1 μg∕mL PpIX, 1.5% LVF, and 2% BVF at
hour 0, 2, and 5, for 0% TVF [(a) through (c)] and 5% TVF [(d) through (f)].
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3.4 PpIX Fluorescence with Variations in
Background Scattering and Absorption
Figure 8 contains estimates of PpIX fluorescence and concen-
tration recovered in phantoms with variations in both BVF and
LVF. Figures 8(a) and 8(b) show fitted PpIX fluorescence inten-
sity versus known PpIX concentrations for variation in BVF
(range: 0.5% to 3%) at 0 and 5 h sampled time points, while
Figures 8(c) and 8(d) display the same metrics for multiple
LVF (range: 1% to 2%). Here, each combination of Intralipid
and whole blood yielded a linear relationship between fitted
PpIX fluorescence intensity and PpIX concentration, with an
average Pearson product correlation coefficient of r > 0.99
for each individual optical property set. The raw fluorescence
data show a stratification in intensity that is due to attenuation
from background optical properties, with mean absolute resid-
uals of <34% and <13% for BVF and LVF variations, respec-
tively. Figure 8 also shows quantitative estimates of PpIX
concentration versus known concentration for variations in both
BVF [(e) and (f)] and LVF [(g) and (h)] for 0- and 5-h
time points. These data are corrected for the influence of back-
ground optical properties and show reduced variability with
respect to variation in both BVF and LVF, with mean absolute
residuals of <10% and <7%, respectively. The aggregate PpIX
concentrations show a strong linear relationship between esti-
mated and known concentration at both 0 and 5 time points
(r > 0.99). The observed stability in PpIX fluorescence and
concentration indicates that blood and Intralipid can reliably
be used as absorbing and scattering agents in optical phantoms
bearing PpIX even though they are not established standards.
4 Discussion
The data presented in this study are used to identify a recipe for
tissue-simulating optical phantoms that yield proportional and
stable PpIX fluorescence emissions. Optical measurements
with low TVF (i.e., ≤0.1%) presented a linear proportionality
between fluorescence intensity and PpIX concentration (0.1
to 10 μg∕mL) for a range of LVF (1% to 2%) and BVF
(0.5% to 3%) that was stable for 5 h after mixing. Data also
provided multiple insights into how surfactant influences PpIX
fluorescence emission within the phantoms, including: (I) mea-
surements showed aggregation-based quenching of PpIX fluo-
rescence emission in aqueous nonturbid phantoms with no
surfactant. (II) No difference in PpIX fluorescence intensity
was observed for Intralipid diultions of (1% to 2% IVF) with or
without additional surfactant, indicating that when Intralipid is
used as a scattering agent, the amphipathic phospholipids con-
tained in the lipid emulsion formulation act as a surfactant that
prevents aggregation; this result was confirmed with measure-
ments using egg yolk. (III) For phantoms containing whole
blood and TVF > 0.1%, we observed a temporal degradation
in PpIX fluorescence intensity, with the rate of degradation depen-
dent on surfactant concentration. These distortions were caused by
an interaction between surfactant and whole blood, and this inter-
action was avoided by using little or no Tween (i.e., ≤0.1% vol-
ume fraction) in phantoms containing whole blood.
The optical phantoms presented in this study can be tuned to
mimic the endogenous optical properties experienced in tissue.
Intralipid is widely used in the field of biomedical optics as a
scattering source that is relatively inexpensive, stable, and rep-
resentative of the reduced scattering spectrum reported in
tissue.26–28 This study highlights an additional advantage, that
the lipid formulation contains surfactant that prevents PpIX
Time (h)
Fig. 7 PpIX estimate over time of refrigerated and unrefrigerated
phantoms for 0.5% and 5% Tween volume fraction.
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Fig. 8 Raw PpIX fluorescence vs. concentration for multiple blood concentrations at time (a) 0 and (b) 5 h
following phantom preparation. Raw PpIX fluorescence vs. concentration for multiple Intralipid concen-
trations at time (c) 0 and (d) 5 h following phantom preparation. Quantitative PpIX estimates versus con-
centrations for multiple blood concentrations at time (e) 0 and (f) 5 h following phantom preparation.
Quantitative PpIX estimates versus concentration for multiple Intralipid concentrations at time (g) 0
and (h) 5 h following phantom preparation. Line in panels (e) through (h) shows linear fit to the data
from all blood/intralipid volumes.
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aggregation. The use of bovine whole blood as the background
absorber is well-characterized 29 and offers a tailored match of
the absorption bands at excitation and emission to endogenous
absorption in tissue. Replicating the endogenous spectral
absorption characteristics of tissue across the UV–VIS wave-
length range with a mixture of dyes can be difficult to achieve,
with blue dyes often containing additional peaks in the visible
wavelength range. The accurate recovery of quantitative PpIX
concentration in the presence of variations to both blood and
lipid volume fractions indicate that the absorption and scatter-
ing-based attenuation of fluorescence intensity observed in these
phantoms were well described by an analytical model of light
transport. Additionally, the data presented in this study showed
no fluorescence distortions that could be attributable to inter-
actions between Intralipid and bovine whole blood over a
range of mixtures that replicate physiologically relevant optical
properties.
This study defines a stable and useful phantom as one that
returns a linear response between fluorescence intensity and the
contained PpIX concentration. It is worth noting that this study
does not independently measure the quantum yield of PpIX in
the phantoms. While differences in the quantum yield between
phantom and tissue would limit the direct use of fluorescence
emission data as a standard curve to convert PpIX fluorescence
intensities measured in tissue to PpIX concentration, such a con-
version would likely differ by a scalar factor. The linear response
of PpIX fluorescence-concentration identified for each set of
optical properties suggests that changes to background scatter-
ing and absorption were not dynamically influencing the quan-
tum yield. Therefore, these fluorescence intensity data can be
used to characterize the sensitivity of raw fluorescence emission
to background scattering and absorption, and an assumed quan-
tum yield could be used to recover a linearly proportional esti-
mate of PpIX concentration.
It should be noted that some aspects of these phantoms
requires careful consideration to yield repeatable results. One
consideration is that samples containing whole blood are sus-
ceptible to settling, with the blood occasionally coming out of
solution and pooling at the bottom of the phantom. Gentle, but
thorough, mixing of the phantom can solve this issue and it was
observed that the addition of 0.1% Tween helped to keep the
blood in solution. Another consideration is that accurate spectral
analysis using whole blood as an absorber requires the user to
measure the hematocrit of the blood to establish the concentra-
tion of total hemoglobin, which specifies the absorption spec-
trum. Conversely, the data indicate that the phantoms do not
need to be refrigerated, with stable fluorescence response
yielded over a 5-h period at ambient room temperature.
In conclusion, the present study provides data to guide the
construction of tissue-simulating optical phantoms that yield
a stable and repeatable relationship between PpIX fluorescence
emission and PpIX concentration. The recommended recipe
offers a wide range of PpIX concentrations, as well as back-
ground scattering and absorption spectra well-matched to
mimic tissue. The standardization of optical phantoms bearing
PpIX would make results from different systems that are inves-
tigated by different research groups directly comparable.
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